[go: up one dir, main page]

ATE338751T1 - Benzimidazolderivate mit vitronectinrezeptor- antagonistischer wirkung - Google Patents

Benzimidazolderivate mit vitronectinrezeptor- antagonistischer wirkung

Info

Publication number
ATE338751T1
ATE338751T1 AT99962691T AT99962691T ATE338751T1 AT E338751 T1 ATE338751 T1 AT E338751T1 AT 99962691 T AT99962691 T AT 99962691T AT 99962691 T AT99962691 T AT 99962691T AT E338751 T1 ATE338751 T1 AT E338751T1
Authority
AT
Austria
Prior art keywords
benzimidazole derivatives
antagonistic effect
receptor antagonistic
vitronectin receptor
vitronectin
Prior art date
Application number
AT99962691T
Other languages
English (en)
Inventor
Bernard R Neustadt
Elizabeth M Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE338751T1 publication Critical patent/ATE338751T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99962691T 1998-11-30 1999-11-29 Benzimidazolderivate mit vitronectinrezeptor- antagonistischer wirkung ATE338751T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20161198A 1998-11-30 1998-11-30

Publications (1)

Publication Number Publication Date
ATE338751T1 true ATE338751T1 (de) 2006-09-15

Family

ID=22746536

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962691T ATE338751T1 (de) 1998-11-30 1999-11-29 Benzimidazolderivate mit vitronectinrezeptor- antagonistischer wirkung

Country Status (12)

Country Link
EP (1) EP1135374B9 (de)
JP (1) JP4480117B2 (de)
CN (1) CN1161340C (de)
AR (1) AR021427A1 (de)
AT (1) ATE338751T1 (de)
AU (1) AU1908400A (de)
CA (1) CA2353063C (de)
CO (1) CO5140112A1 (de)
DE (1) DE69933135T2 (de)
ES (1) ES2273517T3 (de)
PE (1) PE20001427A1 (de)
WO (1) WO2000032578A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148349C (zh) * 1999-04-07 2004-05-05 参天制药株式会社 N-取代-N′-取代脲衍生物及其用作TNF-α生成抑制剂的用途
WO2000069810A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP2527430B1 (de) 2007-06-07 2014-12-31 Novozymes A/S Verfahren zur Herstellung eines Produkts auf Teigbasis
EP2595488B1 (de) 2010-07-21 2019-12-04 Novozymes A/S Verfahren zur herstellung von backwaren mit alterungsbeständige amylase und peptidase
CA2939021C (en) 2014-02-11 2022-07-12 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
EP3105209B1 (de) 2014-02-11 2019-08-21 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amine als midh1-inhibitoren
CN104694290A (zh) * 2014-05-07 2015-06-10 宁波职业技术学院 一种洗脚皂
ES2814151T3 (es) 2014-10-23 2021-03-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 1-Ciclohexilo-2-fenilaminobenzimidazoles como inhibidores de MIDH1 para el tratamiento de tumores
JP6783756B2 (ja) 2014-10-23 2020-11-11 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ mIDH1阻害剤としてのベンゾイミダゾール−2−アミン
JP6830909B2 (ja) 2015-06-08 2021-02-17 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ mIDH1阻害剤としてのN−メンチルベンズイミダゾール
EP3322694B1 (de) 2015-07-16 2020-02-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazole als midh1-inhibitoren
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CA3174507A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
CA2193966A1 (en) * 1994-06-29 1996-01-11 Fadia El-Fehail Ali Vitronectin receptor antagonists

Also Published As

Publication number Publication date
AU1908400A (en) 2000-06-19
CO5140112A1 (es) 2002-03-22
PE20001427A1 (es) 2000-12-18
WO2000032578A8 (en) 2002-02-07
JP2002531441A (ja) 2002-09-24
CA2353063C (en) 2009-06-16
ES2273517T3 (es) 2007-05-01
JP4480117B2 (ja) 2010-06-16
CN1333755A (zh) 2002-01-30
DE69933135T2 (de) 2007-08-09
DE69933135D1 (de) 2006-10-19
CA2353063A1 (en) 2000-06-08
EP1135374B9 (de) 2007-02-21
CN1161340C (zh) 2004-08-11
AR021427A1 (es) 2002-07-17
EP1135374A1 (de) 2001-09-26
EP1135374B1 (de) 2006-09-06
WO2000032578A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
ATE264317T1 (de) Benzimidazol-derivate mit antihistaminischer wirkung
ATE246700T1 (de) Benzimidazolderivate
DE60219513D1 (de) Sauerstoffbefeuerter zirkulierender wirbelschichtdampferzeuger
IS5706A (is) Adenosín A3 viðtakastillar
EE200300244A (et) 3-aroüülindooli derivaadid ja nende kasutamine CB2-retseptorite agonistidena
DE60026169D1 (de) Selektive neurokinin-antagonisten
MA26816A1 (fr) Derives d'amino-triazolopyridine
ATE456559T1 (de) Piperazinderivate mit ccr1-rezeptor- antagonistischer wirkung
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
ATE338751T1 (de) Benzimidazolderivate mit vitronectinrezeptor- antagonistischer wirkung
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
IT1314191B1 (it) Derivati isossazolcarbossamidici
NO20004503L (no) Vitronectin-reseptor-antagonister
NO20013997L (no) Reseptoranalyse
EE200200204A (et) Asendatud bensimidasooli preparaat
ATE277043T1 (de) Vitronectin rezeptor antagonist
DE60012062D1 (de) Fluorierte Triazinderivate
NO20015237D0 (no) Integrinreseptor-antagonister
FI990800A0 (fi) Verkkoelementti
TR200002831A3 (tr) Kinolin-4-Il türevleri I
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
NO20010620D0 (no) Vitronektinreseptor-antagonister
NO20011779D0 (no) Ureidopiperidinderivater som selektive humane NK3 reseptor antagonister
ITMI991704A0 (it) Derivati tienopirancarbossamidici

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties